编者按：2024年美国临床肿瘤学会胃肠道肿瘤研讨会（2024 ASCO Gastrointestinal Cancers Symposium，ASCO GI 2024）将于美国当地时间2024年1月18～20日在旧金山召开。近日ASCO GI官网披露了摘要标题，现整理将于1月19日登场的中国肝胆胰肿瘤研究，以飨读者。排名不分先后，如有遗漏或错误，欢迎广大读者朋友提醒及指正。
01
口头报告专场
Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.
KRAS G12C抑制剂glecirasib (JAB-21822)在胰腺癌和其他实体肿瘤患者中的初步活性和安全性结果
Presenter: 李健（北京大学肿瘤医院）
Abstract: 604
Adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm): A phase 2, multicenter, randomized controlled trial.
窄切缘(≤1cm)肝癌根治性切除术后辅助放疗:一项2期、多中心、随机对照试验。
Presenter: 匡铭（中山大学附属第一医院）
Abstract: 722
02
壁报专场
Trials in Progress Poster Session Level 1, West HallTrials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
安洛替尼联合派安普利单抗和肝动脉输注化疗(HAIC)在一线治疗不可切除的肝细胞癌
Presenter: Gong-Rang Chen（益阳市中医医院）
Abstract: TPS579
| Poster Bd #: P8
A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
一项评估安洛替尼联合派安普利单抗治疗晚期难治性胆道癌安全性和有效性的II期研究
Presenter:贺小军（唐都医院）
Abstract: TPS582
| Poster Bd #: P11
Poster Session Level 1, West HallPoster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
不可切除肝细胞癌(uHCC)患者的真实生存结局和治疗模式:来自OREIOS研究的结果
Presenter: Stephen Chan（中国香港中文大学）
Abstract: 449
| Poster Bd #: A14
Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).
卡瑞利珠单抗+ 阿帕替尼vs 索拉非尼作为不可切除的肝细胞癌(uHCC)患者的一线治疗CARES-310 实验(PROs) <65或≥65岁(yo)患者的报告结果
Presenter: Stephen Chan（中国香港中文大学）
Abstract: 456
| Poster Bd #: B1
Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
不可切除肝细胞癌的一线免疫联合治疗:成本-效益分析
Presenter: 文凤（四川大学华西医院）
Abstract: 469
| Poster Bd #: B14
Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.
Tinengotinib (TT-00420)联合阿替利珠单抗治疗中国胆道癌(BTC)患者:Ib/II期研究的初步疗效和安全性结果
Presenter: 张攀攀（北京大学肿瘤医院）
Abstract: 473
| Poster Bd #: B18
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
ZSAB-TOP：替雷利珠单抗(TIS)和ociperlimab (OCI)联合吉西他滨和顺铂(GemCis)作为晚期胆道癌(BTC)一线治疗的2期临床试验
Presenter: 樊嘉（复旦大学附属中山医院）
Abstract: 475
| Poster Bd #: B20
The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial.
经动脉化疗栓塞联合卡度尼利单抗和仑伐替尼治疗不可切除肝癌的有效性和安全性:一项II期临床试验
Presenter: 邵国良（浙江省肿瘤医院）
Abstract: 478
| Poster Bd #: C3
Efficacy and safety of surufatinib in biliary tract cancer: Preliminary results of a real-world study.
索凡替尼治疗胆道癌的疗效和安全性:一项真实世界研究的初步结果
Presenter: 张宗利（山东大学齐鲁医院）
Abstract: 486
| Poster Bd #: C11
A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.
单组、多中心II期研究:替雷利珠单抗联合仑伐替尼和GEMOX作为潜在可切除的局部晚期胆道癌(ZSAB-TransGOLP)的转化治疗:初步分析
Presenter:樊嘉（复旦大学附属中山医院）
Abstract: 488
| Poster Bd #: C13
Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
信迪利单抗、贝伐珠单抗加吉西他滨和白蛋白结合紫杉醇联合治疗最初不可切除胆囊癌的疗效和安全性:一项前瞻性单臂II期研究
Presenter: 王苗（复旦大学附属肿瘤医院）
Abstract: 489
| Poster Bd #: C14
Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
ALTER-H006的初步结果:TQB2450联合安罗替尼作为根治术后复发风险高的肝细胞癌(HCC)辅助治疗的II期研究
Presenter: 毛先海（湖南省人民医院）
Abstract: 494
| Poster Bd #: D1
Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
安罗替尼+ TQB2450 (PD-L1阻断剂)联合白蛋白紫杉醇和顺铂作为晚期胆道癌的一线治疗:单组、开放标签II期临床试验
Presenter: 靳水玲（郑州大学第一附属医院）
Abstract: 498
| Poster Bd #: D5
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
呋喹替尼联合信迪利单抗+经动脉化疗栓塞(TACE)治疗不可切除的肝细胞癌:一项单臂II期研究
Presenter: 邵国良（浙江省肿瘤医院）
Abstract: 499
| Poster Bd #: D6
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗治疗不可切除肝细胞癌的疗效和安全性:一项单组II期研究
Presenter: Yongkang Xu（南昌大学第二附属医院）
Abstract: 500
| Poster Bd #: D7
Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.
围手术期仑伐替尼联合替雷利珠单抗+经导管动脉化疗栓塞治疗可切除的复发高风险肝细胞癌:一项前瞻性单臂2期试验
Presenter: 吴嘉艺（福建省立医院）
Abstract: 503
| Poster Bd #: D10
The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers (BTCs).
一项单臂、开放标签、II期研究的中期分析，研究了ALLEN方案(度伐利尤单抗+白蛋白紫杉醇和仑伐替尼)在不可切除胆道癌(BTCs)患者中的应用
Presenter: Zhifang Li （中国人民解放军总医院第五医学中心）
Abstract: 504
| Poster Bd #: D11
Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study.
辅助TACE加仑伐替尼与单独TACE治疗肝细胞癌术后复发高风险患者的比较:一项前瞻性对照研究
Presenter: 张斌（浙江大学医学院附属邵逸夫医院）
Abstract: 505
| Poster Bd #: D12
Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial.
ALTER-H004研究的最新结果:安罗替尼联合TACE作为术后复发高风险肝细胞癌(HCC)患者的辅助治疗:单臂、多中心、II期临床试验
Presenter: Zheng Wu（西安交通大学第一附属医院）
Abstract: 513
| Poster Bd #: D20
Neo-adjuvant tislelizumab combined with lenvatinib treatment for resectable, recurrent hepatocellular carcinoma.
新辅助替雷利珠单抗联合仑伐替尼治疗可切除的复发性肝细胞癌
Presenter: 匡铭（中山大学附属第一医院）
Abstract: 517
| Poster Bd #: E4
Prognostic value of minimal residual disease profiling in resectable hepatocellular carcinoma.
可切除肝细胞癌微小残留病灶的预后价值
Presenter: 胡捷（复旦大学附属中山医院）
Abstract: 530
| Poster Bd #: E17
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma.
综合多组学分析转移性肝细胞癌的时空演变
Presenter:孙云帆（复旦大学附属中山医院）
Abstract: 556
| Poster Bd #: G4
Predictive machine learning models for survival outcomes in patients with pancreatic cancer.
胰腺癌患者生存结果的预测机器学习模型
Presenter: Yang-Chen Shen（中国台湾成功大学）
Abstract: 625
| Poster Bd #: J12
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
antroquinonol联合白蛋白紫杉醇和吉西他滨治疗转移性胰腺癌的I/II期研究
Presenter: Yan-Shen Shan（中国台湾成功大学）
Abstract: 648
| Poster Bd #: K17
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
安罗替尼联合化疗作为胃肠道肿瘤伴不可切除肝转移患者的一线治疗:来自多队列、多中心II期试验ALTER-G-001-cohort C的最新结果
Presenter: 吴珺玮（上海交通大学医学院附属瑞金医院）
Abstract: 653
| Poster Bd #: L2
The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with metastatic pancreatic cancer (mPC).
转移性胰腺癌(mPC)患者ALLEN方案(度伐利尤单抗+白蛋白紫杉醇和仑伐替尼)单组、开放标签、II期研究的中期分析
Presenter: 陈美霞（中国人民解放军总医院）
Abstract: 658
| Poster Bd #: L7
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
索凡替尼联合信迪利单抗、白蛋白紫杉醇和吉西他滨(AG)作为局部晚期或转移性胰腺腺癌(mPDAC)患者一线治疗的II期研究的初步结果
Presenter: 张东生（中山大学肿瘤防治中心）
Abstract: 659
| Poster Bd #: L8
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
索凡替尼联合卡瑞利珠单抗、白蛋白紫杉醇和S-1 (NASCA)作为转移性胰腺腺癌(mPDAC)一线治疗的1b/2期研究的最新结果
Presenter: Ru Jia（中国人民解放军总医院第五医学中心）
Abstract: 671
| Poster Bd #: L20